Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107435 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacological Research, 2024. Verfasst von Xiao Ran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Departmen…. Hauptthemen laut MEDLINE: Tissue Kallikreins, Ischemic Stroke, Reperfusion Injury, Neuroprotective Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Province Natural Science Foundation.
Themen: Schlaganfall
Abstract (Originalsprache)
Tissue kallikrein (TK) has emerged as a potential neuroprotective agent in ischemic stroke (IS), yet the optimal timing and mechanisms of TK therapy remain unclear. Here, we established a causal link between lower baseline TK levels and an increased risk of stroke through a retrospective, multicenter cohort study involving 2115 initially non-stroke subjects monitored for 5 years. Sequentially, we observed a notable increase in bradykinin receptor 2 (B2R) levels during the ischemic phase of the IS model, while levels of TK and bradykinin receptor 1 (B1R) remained stable. Intriguingly, both B1R and B2R exhibited a significant elevation 24 h after reperfusion. Further investigations in preclinical models demonstrated that TK supplementation activates the PI3K/AKT signaling pathway via enhanced B2R expression during the ischemic phase, leading to nuclear translocation of Hif-1α. This activation enhances the expression of VEGF and eNOS, thereby fortifying the neurovascular unit. Moreover, it suppresses the activation of the kallikrein-kinin system induced by reperfusion injury, effectively reducing inflammation, ROS production, apoptosis, and endothelial barrier dysfunction. Thus, our findings highlight the significance of TK supplementation during the ischemic phase in attenuating reperfusion-induced injury in IS, providing a mechanistic rationale for determining the optimal timing for TK supplementation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huaz…
- Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Chi…
- Department of Anesthesiology, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong U…
Förderung
- National Natural Science Foundation of China
- Hubei Province Natural Science Foundation
Zitieren
APA
Ran, X., Xu, T., Ruan, H., Wang, X., & Zhang, Q. (2024). Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107435
Vancouver
Ran X, Xu T, Ruan H, Wang X, Zhang Q. Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107435
BibTeX
@article{Ran2024,
author = {Ran, Xiao and Xu, Tingting and Ruan, Hang and Wang, Xiaochuan and Zhang, Qin},
title = {Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107435}
}
EUVIMED